Maravai LifeSciences Reaches New 52-Week Low at 5.93
MRVI Stock | USD 5.93 0.50 9.21% |
Under 61% of all Maravai Lifesciences' traders are looking to take a long position. The analysis of overall sentiment of trading Maravai Lifesciences Holdings stock suggests that some investors are interested at this time. Maravai Lifesciences' investing sentiment shows overall attitude of investors towards Maravai Lifesciences Holdings.
Maravai |
Shares of Maravai LifeSciences Holdings, Inc. hit a new 52-week low during trading on Wednesday . The company traded as low as 5.93 and last traded at 6.12, with a volume of 352119 shares trading hands. The stock had previously closed at 6.88. Analysts Set New Price Targets A number
Read at thelincolnianonline.com
Maravai Lifesciences Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Maravai Lifesciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Maravai Lifesciences Fundamental Analysis
We analyze Maravai Lifesciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Maravai Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Maravai Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Maravai Lifesciences is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Maravai Lifesciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Maravai Lifesciences stock to make a market-neutral strategy. Peer analysis of Maravai Lifesciences could also be used in its relative valuation, which is a method of valuing Maravai Lifesciences by comparing valuation metrics with similar companies.
Peers
Maravai Lifesciences Related Equities
ARQT | Arcutis Biotherapeutics | 4.53 | ||||
FOLD | Amicus Therapeutics | 3.05 | ||||
PTGX | Protagonist Therapeutics | 2.72 | ||||
ABUS | Arbutus Biopharma | 2.17 | ||||
HALO | Halozyme Therapeutics | 1.36 | ||||
IMVT | Immunovant | 0.84 | ||||
KRYS | Krystal Biotech | 0.73 | ||||
INCY | Incyte | 0.51 | ||||
CYTK | Cytokinetics | 0.1 | ||||
ARGX | Argenx NV | 0.18 | ||||
INSM | Insmed | 0.21 | ||||
RARE | Ultragenyx | 0.47 | ||||
ROIV | Roivant Sciences | 1.06 | ||||
APLS | Apellis Pharmaceuticals | 1.09 | ||||
AKRO | Akero Therapeutics | 1.54 | ||||
DNLI | Denali Therapeutics | 1.88 | ||||
ASND | Ascendis Pharma | 2.08 | ||||
HRMY | Harmony Biosciences | 2.30 | ||||
EWTX | Edgewise Therapeutics | 2.58 | ||||
ALEC | Alector | 4.33 | ||||
AGIO | Agios Pharm | 5.39 | ||||
LEGN | Legend Biotech | 8.96 |
Complementary Tools for Maravai Stock analysis
When running Maravai Lifesciences' price analysis, check to measure Maravai Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Maravai Lifesciences is operating at the current time. Most of Maravai Lifesciences' value examination focuses on studying past and present price action to predict the probability of Maravai Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Maravai Lifesciences' price. Additionally, you may evaluate how the addition of Maravai Lifesciences to your portfolios can decrease your overall portfolio volatility.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |